Journal
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
Volume 9, Issue 12, Pages 861-876Publisher
Becaris Publishing
DOI: 10.2217/cer-2020-0063
Keywords
chemotherapy; crizotinib; docetaxel; entrectinib; matching-adjusted indirect comparison; non-small cell lung cancer; NSCLC; pemetrexed; ROS1
Categories
Funding
- F. Hoffmann-La Roche Ltd
Ask authors/readers for more resources
Aim: To perform indirect treatment comparisons of entrectinib versus alternative ROS1 fusion-positive non-small cell lung cancer treatments. Methods: Relevant studies with crizotinib and chemotherapy as comparators of interest identified by systematic literature review were selected for matching-adjusted indirect comparison by feasibility assessment. Matching was based on known prognostic/predictive factors and scenario analyses were used for unreported confounders in comparator trials. Results: Entrectinib yielded significantly better responses versus crizotinib in all scenarios (odds ratio [OR]: 2.43-2.74). Overall survival (hazard ratio: 0.47-0.61) and adverse event-related discontinuation (OR: 0.79-0.90) favored entrectinib. Progression-free survival was similar across treatments, except in one scenario. Conclusion: These results suggested improved outcomes with entrectinib versus crizotinib/chemotherapy and may help to make better informed treatment decisions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available